These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30074208)

  • 1. Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.
    Deng J; Mei H; Shi W; Pang ZQ; Zhang B; Guo T; Wang HF; Jiang XG; Hu Y
    Curr Med Sci; 2018 Jun; 38(3):427-435. PubMed ID: 30074208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyacrylic acid-coated nanoparticles loaded with recombinant tissue plasminogen activator for the treatment of mice with ischemic stroke.
    Huang L; Wang J; Huang S; Siaw-Debrah F; Nyanzu M; Zhuge Q
    Biochem Biophys Res Commun; 2019 Aug; 516(2):565-570. PubMed ID: 31235258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
    Chen HA; Ma YH; Hsu TY; Chen JP
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Plasminogen Activator Modified Nanoparticles for Targeting Thrombolysis in Branch Retinal Vein Occlusion.
    Zhang H; Han S; Zhang L; Guo Y; Li Y
    Cell Mol Biol (Noisy-le-grand); 2022 Mar; 68(3):201-212. PubMed ID: 35988180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function.
    Gautier S; Petrault O; Gele P; Laprais M; Bastide M; Bauters A; Deplanque D; Jude B; Caron J; Bordet R
    Stroke; 2003 Dec; 34(12):2975-9. PubMed ID: 14615621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke.
    Morris DC; Zhang L; Zhang ZG; Lu M; Berens KL; Brown PM; Chopp M
    Stroke; 2001 Nov; 32(11):2635-40. PubMed ID: 11692028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetically targeted thrombolysis with recombinant tissue plasminogen activator bound to polyacrylic acid-coated nanoparticles.
    Ma YH; Wu SY; Wu T; Chang YJ; Hua MY; Chen JP
    Biomaterials; 2009 Jul; 30(19):3343-51. PubMed ID: 19299010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke.
    Niessen F; Hilger T; Hoehn M; Hossmann KA
    Stroke; 2003 Aug; 34(8):2019-24. PubMed ID: 12843350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke.
    Tanne D; Macko RF; Lin Y; Tilley BC; Levine SR;
    Stroke; 2006 Jul; 37(7):1798-804. PubMed ID: 16763191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The JNK inhibitor XG-102 protects from ischemic damage with delayed intravenous administration also in the presence of recombinant tissue plasminogen activator.
    Wiegler K; Bonny C; Coquoz D; Hirt L
    Cerebrovasc Dis; 2008; 26(4):360-6. PubMed ID: 18728363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic insight into neurotoxicity of tissue plasminogen activator-induced thrombolysis products in a rat intraluminal middle cerebral artery occlusion model.
    Oka F; Fujisawa H; Nomura S; Kajiwara K; Kato S; Fujii M; Izuma H; Uozumi K; Gondo T; Suzuki M
    J Neurotrauma; 2009 Sep; 26(9):1577-84. PubMed ID: 19275467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequentially Site-Specific Delivery of Thrombolytics and Neuroprotectant for Enhanced Treatment of Ischemic Stroke.
    Xu J; Wang X; Yin H; Cao X; Hu Q; Lv W; Xu Q; Gu Z; Xin H
    ACS Nano; 2019 Aug; 13(8):8577-8588. PubMed ID: 31339295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke.
    Zhang L; Zhang ZG; Zhang RL; Lu M; Krams M; Chopp M
    Stroke; 2003 Jul; 34(7):1790-5. PubMed ID: 12805500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of recombinant plasminogen activator timing on thrombolysis in a novel rat embolic stroke model.
    Ma Y; Li L; Niu Z; Song J; Lin Y; Zhang H; Du G
    Pharmacol Res; 2016 May; 107():291-299. PubMed ID: 27038532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions.
    Seitz RJ; Meisel S; Moll M; Wittsack HJ; Junghans U; Siebler M
    Neurology; 2004 Jun; 62(11):2110-2. PubMed ID: 15184627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.
    Yagi K; Kitazato KT; Uno M; Tada Y; Kinouchi T; Shimada K; Nagahiro S
    Stroke; 2009 Feb; 40(2):626-31. PubMed ID: 19095969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion.
    Pfefferkorn T; Rosenberg GA
    Stroke; 2003 Aug; 34(8):2025-30. PubMed ID: 12855824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil migration participates in the side effect of recombinant human tissue plasminogen activator.
    Huang Y; Han Z; Shen T; Zheng Y; Yang Z; Fan J; Wang R; Yan F; Tao Z; Luo Y; Liu P
    CNS Neurosci Ther; 2024 Jul; 30(7):e14825. PubMed ID: 38954749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons.
    Runge MS; Harker LA; Bode C; Ruef J; Kelly AB; Marzec UM; Allen E; Caban R; Shaw SY; Haber E; Hanson SR
    Circulation; 1996 Sep; 94(6):1412-22. PubMed ID: 8823001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations.
    Kilic E; Bähr M; Hermann DM
    Stroke; 2001 Nov; 32(11):2641-7. PubMed ID: 11692029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.